Efficacy of brexpiprazole on agitation in patients with dementia due to Alzheimer’s disease exhibiting behaviors most bothersome to caregivers: <i>post hoc</i> pooled analysis of two randomized controlled trials

Agitation behaviors that are most bothersome to caregivers of patients with dementia due to Alzheimer's disease (including excessive motor activity, verbal aggression, and physical aggression) were generally well represented in the brexpiprazole trials. In patients frequently exhibiting these bothersome behaviors, fixed-dose brexpiprazole 2 or 3 mg/day was associated with larger improvements than placebo.